Doctor Oliver Kepp

A recognised expert in cancer immunotherapy, Dr Oliver Kepp is Director of Research at Inserm, working within the "Metabolism, Cancer and Immunity" team (Inserm U1138 / Gustave Roussy / Université Paris-Saclay). He also leads the PACRI automated cell screening platform at Gustave Roussy.

His research adopts an integrative systems biology approach, combining cell biology, immunology, and oncology. His primary goal is to identify novel anticancer compounds capable of triggering a robust immune response, thereby enhancing the effectiveness of existing therapies. His work focuses particularly on tumour immunogenicity and the elucidation of mechanisms of action of promising therapeutic agents.

Dr Kepp holds a PhD in Molecular Biology from Humboldt University in Berlin. He conducted his postdoctoral research at the Max Planck Institute for Infection Biology before joining Professor Guido Kroemer’s laboratory at Gustave Roussy in 2007. He was appointed Director of Research at Inserm in 2022.

Author of over 350 scientific publications, Dr Kepp ranks among the most highly cited researchers worldwide in the field of cell biology. He sits on several international editorial boards, is co-founder of Samsara Therapeutics (Oxford, UK), and has served as Associate Director of the European Academy of Tumour Immunology since 2019.

He has been recognised as a Highly Cited Researcher by Clarivate for seven consecutive years since 2018 and received the Biology and Biochemistry Leader Award (Research.com) in both 2022 and 2023. He is considered among the world’s most influential scientists in the fields of biology and biochemistry.